Loading
Adagloxad simolenin is OBI Pharma's vaccine against the tumour sugar Globo H, in the phase 3 GLORIA trial as adjuvant treatment for triple-negative breast cancer that expresses the antigen.
OBI Pharma of Taiwan developed adagloxad simolenin (OBI-822) from Samuel Danishefsky's Globo H synthesis. After a phase 2 trial in metastatic breast cancer showed benefit only in patients who mounted an antibody response, the phase 3 GLORIA trial tests it with the adjuvant OBI-821 in the adjuvant setting for Globo H-positive triple-negative breast cancer at high risk of recurrence.
A Globo H glycan conjugated to a carrier protein, given with a saponin adjuvant, to raise antibodies against Globo H, a sugar antigen on breast and other epithelial cancer cells.
1.Adagloxad simolenin slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Adagloxad simolenin" OR ABSTRACT:"Adagloxad simolenin" OR TITLE:"OBI-822" OR ABSTRACT:"OBI-822") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Adagloxad simolenin, not a curated reading list.
Shares Dendritic cell vaccines and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Triple-negative breast cancer (TNBC) and the tag pipeline.